SBIR/STTR Research Award

PURGING PROGENITOR CELL BY PULSED ELECTRIC FIELDS

Award identifier f23e1af09646e717fad3637409e2f9679a4dcd7f77427b64bb102e6a586218c7Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$439,764

Program and phase

SBIR · Phase II

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Science Research Laboratory, Inc
Proposal award date
Not reported
Contract end date
Not reported
UEI
MKKPT9RCLJQ1
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Provided by Applicant): High dose chemotherapy is now a commonly used approach for treatment of hematologic and other cancers, but causes severe myelosuppression requiring progenitor cell infusions. Purging cancer cells from infusions, while maintaining progenitor cells, is an important goal in optimizing the curative potential of this technology. Current purging techniques have limited efficiency and demand intensive time, technology and cost. We have demonstrated a new technology that selectively kills larger cells (including tumor cells) while preserving or enriching hematopoietic progenitor cells, and does so rapidly, profoundly and inexpensively. In phase II, we will apply this technology to a relevant hematologic cancer model (multiple myeloma). Process parameters will be refined to achieve complete tumor purging and progenitor cell preservation/enrichment from tumor-seeded blood or cord blood cells. Sensitive and accurate cell enumeration will be achieved through flow cytometry, tumor regrowth assays, real-time PCR, progenitor cell quieseence/pluripotency assays, and in vivo hematopoietic reconstitution and malignancy assessment in NOD/SCIDt,B2m about mice. We will then apply refined parameters and assessment techniques to clinical volumes of bone marrow cells from myeloma patients, utilizing an optimized, clinical-scale flowing process apparatus. We anticipate the Phase III effort will involve Phase II clinical trials supported by a major biomedical partner. PROPOSED COMMERCIAL APPLICATION: We expect PEF cell-size specific inactivation technology to be an effective transplant tissue purging strategy for post-intensive-therapy patient support. With the propose refinements and assessments, it should provide an approach for rapid, cost-effective, high purity isolation of stem cells from progenitor cell preparations, which will open research, clinical, gene therapy and stem cell banking markets. Our market analysis indicates that the total revenues for this technology may eventually reach $100 million per year.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

228 SBIR/STTR records share this UEI (1984–2020). Reported award amounts total $66,288,679. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Defense, Department of Energy, National Science Foundation, Department of Health and Human Services, National Aeronautics and Space Administration, Department of Transportation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.